This study aimed to investigate the activity of the antioxidant enzyme superoxide dismutase (SOD) in the three main cell types in chronic myeloproliferative disorders (CMPD) patients, i.e. polymorphonuclear leucocytes (PMNLs), erythrocytes and thrombocytes, prior to therapy. Patients with reactive neutrophilia (RN) and healthy volunteers were included as controls. The SOD activity of PMNLs was significantly decreased in CMPD and RN patients compared with healthy volunteers, whereas the SOD activity of erythrocytes was found to be significantly increased in patients with CMPD and RN compared with healthy volunteers. There were no significant differences in the SOD activity of thrombocytes between CMPD patients, RN patients or healthy volunteers. This study indicates that the activity of the SOD enzyme in two cell types is different in CMPD patients compared with healthy subjects. Thus, SOD activity may be altered dependent on cell type and due to specific cell function.
Introduction
The relationship between haematological malignancies and free oxygen radicals is not clear. Production of reactive oxygen species (ROS) is inevitable in cells that use aerobic metabolism for energy production. 1 ROS are known to play a dual role in biological systems, since they may be either harmful or beneficial to cells. Furthermore, oxidative stress may inhibit or promote apoptosis, ultimately leading to the development of necrosis, depending on the intensity of the stimulation. Beneficial effects of ROS are involved in the defence against infectious agents and in the function of a number of cellular signalling systems. 2, 3 In contrast, increased steady-state levels of superoxide radicals such as superoxide anion, hydrogen peroxide and hydroxyl anion, whether due to elevated rate of formation or ineffective O Ceneli, R Haznedar, CO Ongun et al. SOD activity in chronic myeloproliferative disorders scavenging, would result in cessation of cell growth, mutagenesis and cell death, the critical damaging effects being on DNA and enzymes. 4 The antioxidant system includes enzymatic and non-enzymatic antioxidant components. Superoxide dismutase (SOD), one of the main antioxidant enzymes, catalyses the dismutation of highly reactive superoxide anions to hydrogen peroxide, a less reactive ROS, and oxygen, protecting cells from injury induced by free radicals. 2 Hydrogen peroxide and other peroxides in the cell are then converted to non-toxic molecules, such as water and molecular oxygen, by metabolic enzymes, such as catalase and glutathione peroxidase (GPx). Antioxidant defences are extremely important as they represent the direct removal of free radicals (pro-oxidants), providing maximal protection for biological sites. 2, 3 The chronic myeloproliferative disorders (CMPDs) are a group of diseases that all result from proliferation of a clone of myeloid cells derived from a neoplastic precursor. In CMPD, unlike acute leukaemias, maturation of neoplastic cells is relatively normal and cells retain some responsiveness to normal physiological controls. 5 Chronic myeloid leukaemia (CML) is also a proliferative clonal disorder of haematopoietic stem cells that results primarily in the expansion of mature myeloid cells, but also includes expansion of the erythroid compartment and an increase in platelets in the peripheral blood. 6, 7 To the authors' knowledge, information pertaining to the assessment of antioxidant capacity, mainly SOD enzyme activity in patients with CMPD, has been limited. In addition, little is known about the function or oxidative status of polymorphonuclear leucocytes (PMNLs) in other types of CMPD, such as essential thrombocythaemia (ET) and myelofibrosis with myeloid metaplasia (MMM). 8 -11 Furthermore, there are no published reports of a study designed to evaluate the SOD activity of all three haematopoietic cell types (PMNLs, erythrocytes and thrombocytes) in CMPD. The clinical course and complications can differ among patients with CMPD, depending on the cell type that is predominantly increased. While hyperviscosity symptoms are related mainly to erythrocyte mass in polycythaemia vera (PV), thrombosis and bleeding frequency are related to the extent of thrombocytosis in ET. Recently, many studies have shown that leucocytosis is a major risk factor for thrombosis in CMPD. 12 -17 The present study aimed to investigate antioxidant status by measuring the activity of the main antioxidant enzyme, SOD, prior to therapy in three cell types in CMPD patients, i.e. in PMNLs, erythrocytes and thrombocytes. For comparison, the activity of SOD was also measured in all three blood cell types of subjects with reactive neutrophilia (RN) and in healthy volunteers.
Patients and methods

PATIENTS
This observational study, which included patients with CMPD, subjects with RN and healthy volunteers, was performed at Gazi University School of Medicine, Ankara, Turkey, between 2001 and 2004. All CMPD patients were newly diagnosed and had not received any previous treatment for their condition. Diagnosis of PV and ET was according to the criteria of the Polycythemia Vera Study Group (PVSG) 18 and MMM was diagnosed according to criteria of the Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. 19 Healthy volunteers, who served as normal controls, were included if they had no acute or chronic diseases such as diabetes, O Ceneli, R Haznedar, CO Ongun et al. SOD activity in chronic myeloproliferative disorders parasitosis, infections or any immune dysfunction. Patients who had infectious complications or inflammatory signs or symptoms were excluded from the study.
All participants gave verbal informed consent prior to participation in the study and the study was approved by Gazi University School of Medicine Ethics Committee.
BLOOD SAMPLING
Peripheral venous blood samples of 10 ml and 3 ml were drawn without stasis from an antecubital vein with a 21-gauge needle into 20 IU/ml heparin-(final heparin/blood v/v was 0.04/10 ml) and ethylene diaminetetraacetic acid (EDTA)-containing tubes, respectively.
CELL PREPARATIONS
For determination of SOD activity in PMNLs, heparinized blood samples were taken and PMNLs were immediately separated by a slight modification of the dextran sedimentation method of Böyum. 20 Blood was allowed to stand for 45 min at 20 -25°C and plasma was then aspirated carefully and centrifuged at 170 g for 10 min. The pellets were suspended in Hanks' balanced salt solution (with glucose) and placed on top of a Ficoll-Hypaque gradient (density 1.077 g/ml) and centrifuged at 400 g for 40 min. Pellets were then washed with 0.34 M sucrose to remove platelets. Any remaining erythrocytes were disrupted by hypotonic lysis with cold distilled water for 30 s. Isotonicity was restored by the addition of 3.5% sodium chloride. The PMNLs were finally washed, suspended very slowly in Hanks' balanced salt solution, sonicated for 1 min (VirSonic 50; VirTis, SP Industries Inc., Gardiner, NY, USA) and centrifuged at 800 g for 10 min to remove nuclei and unbroken cells. The supernatant was treated with 0.2% Triton X-100 to lyse the mitochondria and was again sonicated and centrifuged at 27 000 g for 15 min (Sorvall ® ultracentrifuge; DuPont, Wilmington, NC, USA). Clear supernatants were removed and kept on ice until the subsequent assays were performed.
For determination of SOD activity in erythrocytes and platelets, and for haemoglobin (Hb) determination, heparinized blood samples were taken and whole blood was centrifuged at 250 g for 8 min at 12°C. The platelet-rich plasma was aspirated carefully and centrifuged at 2000 g for 5 min. After removing the supernatant, platelets were treated for 15 min with 1% ammonium oxalate to avoid erythrocyte contamination and centrifuged at 2000 g for 5 min. The supernatant was then discarded and 0.5 ml 3% Triton X-100 solution was added to the platelets. The platelets were lysed by freezing and thawing three times, and the platelet lysates were used for protein and enzymatic assay.
Erythrocyte fractions were washed three times with normal saline, brought to 50% haematocrit and then to a 1:20 dilution in water, mixed and allowed to stand for 30 min at room temperature. The samples were then centrifuged for 30 min at 2000 g. Aliquots from the clear supernatant, which had an optical density of approximately 0.1 at 540 nm, were used for enzymatic assay of SOD activity.
All cell preparations were carried out in the cold (0 -4°C). Protein was determined by the method of Lowry et al. 21 using bovine serum albumin as a standard.
SPECTROPHOTOMETRIC ASSAYS FOR SOD ACTIVITY
The SOD activities of PMNLs, erythrocytes and thrombocytes in the CMPD, RN and O Ceneli, R Haznedar, CO Ongun et al. SOD activity in chronic myeloproliferative disorders healthy volunteer groups were determined by spectrophotometric assay. 22 The assay is based on the inhibitory effect of SOD on the initial rate of 6-hydroxydopamine autooxidation; 6-hydroxydopamine hydroxybromide was prepared at a concentration of 10 -3 M in distilled water sparged with nitrogen, then 0.3 ml was added to 0.05 M phosphate buffer containing 10 -4 M EDTA (pH 7.4) and the above cell preparations so that the final 6-hydroxydopamine concentration was 10 -4 M (final reaction volume 3 ml). The increase in absorbance was measured every 15 s at 490 nm on a Milton Roy Spectronic Array 3000 spectrophotometer (Milton Roy, Rochester, NY, USA). In this experiment, commercially purified SOD (3000 U human erythrocytes; Sigma-Aldrich, St Louis, MO, USA) was added to the samples as standards.
Results were calculated only within the first 45 s when inhibition of 6hydroxydopamine auto-oxidation was linear. The percentage inhibition in the initial rate of change in absorbance caused by the cell preparation or by SOD was calculated. Activity was expressed as percentage inhibition of auto-oxidation in the tested sample and this percentage was then expressed as U/mg protein or U/g Hb (units/g protein for thrombocytes).
All reagent and enzymes were purchased from Sigma-Aldrich.
STATISTICAL ANALYSIS
Statistical analysis was performed using the SPSS ® statistical package, version 10.0 (SPSS Inc., Chicago, IL, USA) for Windows ® . The statistical significance of between-group differences was determined by the Mann-Whitney U-test. The Kruskal-Wallis test was used as the variance analysis method. A Pvalue of < 0.05 was considered to be statistically significant.
Results
PATIENTS
A total of 30 patients with CMPDs, 14 patients with RN and 16 healthy volunteers were included in this study. Mean ± SD age of the patients with CMPD was 56.90 ± 11.37 years (range 36 -75 years) whereas the mean ± SD ages of the patients with RN and the healthy volunteers were 47.00 ± 15.20 years (range 19 -68 years) and 51.69 ± 11.98 years (range 28 -66 years) respectively. The CMPD patients included 14 patients with CML in the chronic phase, seven with PV, five with ET and four with MMM. Patients with CML possessed the Philadelphia chromosome and the other patients with PV, ET and MMM did not. Table 1 summarizes the demographic data of the CMPD and RN patients and healthy volunteers, including sex, age at diagnosis, mean SOD values and the Mann-Whitney U-test statistical comparisons.
The SOD activity of PMNLs was significantly decreased in CMPD patients and in RN patients compared with healthy volunteers, and was also significantly decreased in RN patients compared with healthy volunteers (P < 0.01 for all comparisons). The SOD activity of PMNLs in patients and controls is shown in Table 1 and the range of SOD activity and outlier data are shown in Fig. 1 .
The SOD activity of erythrocytes was markedly and significantly increased in patients with CMPD compared with healthy volunteers (P < 0.01). Interestingly, a marked and significant increase in erythrocyte SOD activity compared with healthy volunteers was also observed in the RN group (P < 0.01), with no statistically significant difference between the CMPD and RN groups for erythrocyte SOD activity. The SOD activity of erythrocytes in patients and controls is shown in Table 1 Fig. 2 .
The SOD activity of thrombocytes between CMPD patients, the RN group and healthy volunteers is shown in Table 1 and the range of SOD activity and outlier data are shown in Fig. 3 . There were no significant differences in the SOD activity of thrombocytes between the three groups. 
CMPD patients RN patients Healthy volunteers
TABLE 1: Demographics and superoxide dismutase (SOD) activity in patients with chronic myeloproliferative disorders (CMPD), patients with reactive neutrophilia (RN) and healthy volunteers
Discussion
In previous studies, different findings have been reported by several groups about oxidative stress and the antioxidant status of leucocytes in various haematological malignancies. Speier and Newburger 23 found that SOD activity decreased in the human promyelocytic leukaemia cell line, HL-60, during myeloid differentiation, with acquisition of most neutrophil functions, including generation of toxic oxygen species. Like other cell lines investigated for their SOD content, HL-60 contained slightly less intracellular SOD enzyme. During dimethylformamide-induced differentiation, which involves a burst in respiratory activity, nicotinamide adenine dinucleotide phosphate oxidase was increased, leading to dramatic increases in the generation of superoxide anions; however, total SOD activity declined. According to these findings, the emerging relationship between the capacities for active free oxygen radical generation and scavenging present a puzzling paradox: an increase in the production of toxic oxygen metabolites is accompanied by a decrease in the detoxification system. 23 Iki et al. 10 studied 57 patients with myeloproliferative disorders (MPD) and eight with chronic myelomonocytic leukaemia (CMML). The MPD patients included 23 patients with CML in chronic phase, eight with CML in blastic crisis, 14 with PV and 12 with ET. Their study showed a marked increase in the superoxide anion-producing capacity of PMNL in patients with chronic MPD compared with normal controls, but not in the CMML patients compared with normal controls. Cooper et al. 9 demonstrated increased oxygen consumption of granulocytes in PV patients. Iki et al. 10 and Cooper et al. 9 did not perform direct SOD activity measurements in the cells; however, there was suggestion of an increase in the superoxide anion producing capacity and a decrease in the oxygen consumption of PMNLs, suggesting a decrease in the detoxification system. Er et al. 24 found that the generation of superoxide anions was significantly elevated and, therefore, SOD activity, especially Cu/Zn SOD activity, was significantly decreased in leucocytes of newly diagnosed and previously untreated acute myeloid leukaemia (AML) patients compared with control subjects. A study by Battisti et al., 2 provided evidence for increased levels of oxidative damage and decreased levels of antioxidant activity in untreated acute lymphoblastic leukaemia (ALL) patients, suggesting a possible link between these two important parameters in this type of cancer. Another important aspect of their work was that no significant difference was observed between the out-oftreatment ALL patients and the control group for SOD activity. They suggested that these findings might be a consequence of the amount of time passed since treatment, demonstrating that the treatment was in fact efficient. 2 In that study, SOD activity was measured in whole blood and is likely to be different from intracellular SOD activity in different cell types.
Devi et al. 25 stated that there was a significant increase in superoxide anions generated by PMLs in leukaemia patients, especially in those patients with acute lymphocytic and non-lymphocytic leukaemia. Mazzone et al. 26 reported that, under unstimulated conditions, the generation of superoxide anions in leukaemia blasts was also induced. The present study clearly showed that the SOD activity of PMNL was significantly (P < 0.01) decreased in CMPD patients compared with healthy volunteers and these findings are in accordance with the previously mentioned O Ceneli, R Haznedar, CO Ongun et al. SOD activity in chronic myeloproliferative disorders studies. The harmful effect of increased ROS may, therefore, be balanced by antioxidant enzymes such as SOD. Alternatively, it is possible that the antioxidant system may be impaired as a consequence of an abnormality in the antioxidative metabolism due to the cancer process. 27 In contrast, Kökoglu et al. 28 found that the SOD activity of leucocytes significantly increased in their study group of 17 acute non-lymphoblastic leukaemia patients, 16 acute lymphoblastic leukaemia patients, six CML patients and eight chronic lymphocytic leukaemia patients compared with 16 healthy volunteers, although the majority of their patients only had acute leukaemia. The 'oxidative burst', as the name implies, is a brief event that occurs only on cell stimulation. In the resting cell, most free oxygen radicals probably derive from mitochondrial oxidative metabolism, which diminishes with myeloid maturation. The finding of the present study, that SOD activity was decreased in the PMNLs of CMPD patients, may be due to relatively normal myeloid maturation in CMPD.
The SOD activity of erythrocytes was markedly and significantly increased in patients with CMPD compared with healthy volunteers in the present study. Interestingly, a marked increase in erythrocyte SOD activity was also observed in the RN group, and there were no statistically significant differences between the CMPD and RN groups for erythrocyte SOD activity. SOD is widely distributed in oxygen-metabolizing cells and has been supposed to protect such cells against the deleterious actions of superoxide radicals. The induction of SOD to defend the cells against superoxide anion damage is logical because erythrocytes transport high concentrations of oxygen, which can lead to ROS as an undesirable side effect. 29, 30 Paoletti and Mocali 30 reported that SOD activity in murine erythroleukaemia cells increased during differentiation induced by hexamethylene bisacetamide. Similarly, Er et al. 24 reported that the activities of SOD and GPx were significantly increased in the erythrocytes of patients with AML compared with normal subjects. Tomoda et al. 31 showed that regulation of the Cu/Zn SOD gene is programmed in erythroid and myeloid differentiation by chemicallyinduced differentiation systems. They have found that SOD activity increased when K562 human leukaemia cells were treated with haemin. It is possible that there is a correlation between SOD activity and the oxygen transport capacity of erythrocytes. Theoretically, if the oxygen requirement of tissues increases, the oxygen load of erythrocytes, ROS and, indirectly, SOD enzyme activity in erythrocytes will also increase. This theory is supported by the findings of Tho and Candlish 32 who found that there was a significant decrease in SOD activity in the erythrocytes of patients with myocardial infarction, congestive cardiac failure and respiratory failure. It seems reasonable to expect that, in patients with long-term reduced tissue perfusion of oxygen, there might be an adaptive reduction in SOD synthesis. On the other hand, the metabolic rate increases in patients with CMPD and infectious diseases. The increased SOD activity of erythrocytes seen in the CMPD and RN patients in the present study may, therefore, be correlated with an increase in metabolic rate and tissue oxygen consumption.
There were no significant differences in the SOD activity of thrombocytes between CMPD patients, RN patients and healthy volunteers in the present study. Previous studies on SOD activity in thrombocytes are few. Leoncini et al. 33 and higher intracellular concentrations of hydrogen peroxide in ET patients than in controls, and the measurement of SOD revealed an increased specific activity of SOD in the thrombocytes of ET patients. Abella et al. 34 have found that the SOD and GPx activities of erythrocytes, thrombocytes and plasma from rheumatoid arthritis patients were unchanged compared with normal controls.
In conclusion, the present study found SOD enzyme activity to be different in all three haematopoietic cell types in patients with CMPD. These findings suggest that SOD enzyme activity and, indirectly, free oxygen radical production, may be altered due to the specific cell functions of these three cell types. The SOD activity of the three cell types may be influenced by intrinsic and extrinsic factors, such as intracellular oxygen content, cytokines, hormones, or growth factors. Further studies are necessary to research the regulatory mechanisms that are involved in controlling the antioxidant activity of each cell type and their potential clinical relevance in CMPD.
